Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2026. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. It does not contain financial results, operational updates, or strategic commentary for the period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not report company-wide financial performance.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details two specific transactions involving the acquisition of American Depositary Shares (ADS) by company executives:
- Dr. Hal Barron (Non-Executive Director): Acquired 2,007.552 ADS at $59.5200 per share on February 20, 2026.
- James Ford (SVP and Group General Counsel): Acquired 47.460 ADS at $59.5200 per share on February 20, 2026.
Both transactions were executed on the New York Stock Exchange (XNYS) and resulted from the reinvestment of dividends within the GSK Executive Supplemental Savings Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk assessments.
Investor Verification Checklist
- Verify the total number of ADS held by Dr. Hal Barron and James Ford post-transaction to assess their total exposure.
- Confirm the dividend reinvestment policy details for the GSK Executive Supplemental Savings Plan.
- Check the market price of GSK ADS on February 20, 2026, to validate the transaction price of $59.5200.
- Review the company's most recent Form 20-F or earnings release for actual financial performance metrics, as this filing contains none.